Christine Gebski - 24 Feb 2022 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
SVP, Filtration & Chromatography
Signature
/s/ Kimberly Brown (Attorney in Fact)
Issuer symbol
RGEN
Transactions as of
24 Feb 2022
Net transactions value
-$34,247
Form type
4
Filing time
28 Feb 2022, 18:09:33 UTC
Previous filing
22 Feb 2022
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +2,124 +6.3% $0.000000 35,668 24 Feb 2022 Direct F1
transaction RGEN Common Stock Tax liability $34,247 -181 -0.51% $189.21 35,487 24 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +2,721 $0.000000 2,721 24 Feb 2022 Common Stock 2,721 $189.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Gebski was awarded 2,124 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
F3 One third of the stock options will vest and become exercisable annually on February 24, 2023, February 24, 2024 and February 24, 2025.

Remarks:

SVP, Filtration & Chromatography